[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583569":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":37,"collaborators":39,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":10,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":53,"maxAge":10,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Regina Elena Cancer Institute","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients suffering from bladder cancer",null,"Patients with a proven diagnosis of muscle-infiltrating or non-muscle-infiltrating bladder cancer, having performance status (PS) 0-1.",{"label":13,"type":10,"description":14,"interventionNames":10},"Healthy persons.","Healthy persons with no previous or current medical history associated with bladder cancer or diagnostic suspicion associated with cancer, to be used as a relative reference.",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Giuseppe Simone, Medical Doctor","CONTACT","+39 0652665005","giuseppe.simone@ifo.it",[22],{"facility":23,"status":24,"city":25,"state":10,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"IRCCS National Cancer Institute \"Regina Elena\"","RECRUITING","Rome","00144","Italy","IT",{"type":30,"coordinates":31},"Point",[32,33],12.51133,41.89193,{"lat":33,"lon":32},[36],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},{"type":38,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[40,42],{"name":41,"class":6},"Azienda Ospedaliera Santa Maria Degli Angeli",{"name":43,"class":6},"Istituto per lo Studio, la Prevenzione e la Rete Oncologica","100583569","analysis-of-urinary-methylation-patterns-via-liquid-biopsy-as-an-early-diagnosis-tool-100583569",false,"NCT06878027","Analysis of Urinary Methylation Patterns Via Liquid Biopsy as an Early Diagnosis Tool","Analysis of Urinary Methylation Patterns Via Liquid Biopsy as a Tool for Early Diagnosis, Non-invasive Monitoring and Prediction of Recurrence Risk in Bladder Cancer","Inclusion Criteria:\n\nPatient group\n\n* age ≥ 18 years\n* proven diagnosis of bladder cancer (infiltrating muscle or non-infiltrating muscle)\n* performance status (PS) 0-1\n* ability to follow the procedures established by the study\n* written consent for participation in the study and data processing\n\ngroup of healthy subjects\n\n* age ≥ 18 years\n* ability to follow the procedures established by the study\n* written consent for participation in the study and data processing\n\nExclusion Criteria:\n\nPatient group\n\n* presence of metastatic bladder cancer\n* lack of autonomy in following the procedures established by the study\n\ngroup of healthy subjects\n\n* previous or current clinical history associated with bladder cancer\n* diagnostic suspicion associated with tumor pathologies\n* ongoing or previous systemic oncological treatments\n* presence of inflammatory and\u002For autoimmune diseases related to particular conditions potentially modifying the methylation profile\n* existing pharmacological treatments (and\u002For any other type of treatment) that could alter the results of the analyzes conducted for the present study\n* lack of autonomy in following the procedures established by the study",true,"ALL","18 Years",{"count":55,"type":56},100,"ESTIMATED","OBSERVATIONAL","Multicenter, observational, prospective, biological pilot study on liquid biopsy, aimed at investigating methylation profiles in relation to the early diagnosis of bladder cancer, to validate the potential of commercially available tests (e.g. BladderCARE, Bladder EpiCheck), to apply and validate tests based on targeted multi-marker or genome wide analyzes via NGS and to identify methylation profiles as a tool to infer clinical outcome.",[60],"Bladder Cancer",[62],"methylation levels in urine samples","2025-03-10",{"date":65,"type":66},"2025-03-14","ACTUAL",{"date":68,"type":66},"2024-08-06",{"date":70,"type":56},"2026-02-06",{"name":5,"class":6},1]